TPST
$2.27
Post-MarketAs of Mar 17, 8:00 PM UTC
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer.
Historical Price
Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.27
Potential Upside
5%
Whystock Fair Value$2.38
Price
UndervaluedFair ValueOvervalued
Fundamentals
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome prolifer...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.60M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-2.18
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-405.03%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.13
Recent News
No recent news found.